

# THE ROLE OF SENSORY NEUROPEPTIDES IN MOUSE MODELS OF NEUROPATHY AND IMMUNE ARTHRITIS

**PhD Thesis**



**Bálint Botz MD**

Science of Pharmacology Doctoral School

Neuropharmacology Program

Program Director: Erika Pintér MD, PhD, DSc

Supervisor: Zsuzsanna Helyes MD, PhD, DSc

UNIVERSITY OF PÉCS, MEDICAL SCHOOL

DEPARTMENT OF PHARMACOLOGY AND PHARMACOTHERAPY AND

JÁNOS SZENTÁGOTHAÍ RESEARCH CENTRE

PÉCS

2015


# INTRODUCTION

## The significance of peptidergic nerves and TRP receptors in pain and inflammation

Capsaicin has mainly been used in painful or inflammatory conditions for centuries, both topically and ingested. In the 1960s it was discovered to selectively desensitize a sensory neuronal subpopulation (Jancsó 1960), and these neurons are therefore called „capsaicin-sensitive afferents”. János Szolcsányi later described that stimulation of these nerves elicits vasodilation and hyperpermeability, which can be blocked by capsaicin pretreatment (Jancsó *et al.* 1967). The receptor responsible for this effect was identified in 1997 and was named Transient Receptor Potential Vanilloid 1 (TRPV1; Caterina *et al.* 1997). TRPV1 is a non-selective cation channel, which serves as a polymodal sensor for various physicochemical stimuli. Besides capsaicin, other vanilloids, such as resiniferatoxin (RTX), can also activate TRPV1. Additionally, it also has endogenous agonists like anandamide, while both bradykinin and prostaglandins are capable of indirectly sensitizing TRPV1 (Szallasi *et al.* 1999). TRPV1 receptors can be found in the dorsal root ganglia, sensory neurons, and thinly myelinated A $\delta$  and C-fibers as well (Caterina *et al.* 1997; Tominaga *et al.* 1998). It plays a central role in hyperalgesia, but chronically it also mediates important anti-inflammatory and analgesic effects (Bölcskei *et al.* 2005). While originally it was thought to be expressed exclusively on neural cells, growing body of evidence supports that TRPV1 is functionally important in various non-neural tissues as well.

Capsaicin-sensitive afferents possess three distinct functions acting as 1) sensory afferents, 2) local and 3) systemic efferents (**Fig. 1.**). The afferent function represents their role in nociception. Meanwhile, proinflammatory peptide mediators are released from the activated peripheral terminals, thereby triggering a neurogenic inflammation (local efferent function; Maggi *et al.* 1988). However, the simultaneously released inhibitory neuropeptides exert anti-inflammatory and analgesic effects both locally and in distant parts of the body through the systemic circulation (systemic efferent or „sensocrine” function; Szolcsányi *et al.* 2004). The discovery of the TRPV1 receptor led to a search for similar receptors conveying the effects of other exogenous irritants and physicochemical painful stimuli. Almost 30 different TRP-superfamily receptors have been identified so far, among which the TRPA1 (Transient Receptor Potential Ankyrin 1) receptor seems to be particularly important for nerve-driven inflammation. It is a sensor for noxious cold, pungent spices like allyl-isothiocyanate (AITC) (found in mustard oil), and it is sensitized by inflammatory mediators such as bradykinin,

similarly to TRPV1. Based on these findings TRPA1 has also been shown to play a central role in nociceptive signaling, neuropathic and inflammatory pain, as well as peripheral neuropeptide release (Nilius *et al.* 2011). Therefore, it was suggested to be a key integrator of neuro-vascular-immune interactions during inflammation (Caceres *et al.* 2009, Pozsgai *et al.* 2010).



**Fig.1.** The three distinct effects of the activation of capsaicin-sensitive sensory nerve endings.

## Peptide mediators in peripheral pain and inflammation

Sensory neuropeptides are released from the activated capsaicin-sensitive primary afferents during inflammation and nerve injury (Brain 1997). Substance P (SP) and other related peptides, such as Neurokinin A (NKA) and Neurokinin B (NKB) were among the first identified tachykinins. Other important sensory neuropeptides are pituitary adenylate-cyclase activating polypeptide (PACAP), vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP), somatostatin, endogenous opioids, and galanin. They regulate the vascular tone and inflammatory cell activity, influence pain behavior and altogether promote a systemic response in order to ameliorate the effects of potentially damaging stimuli. Some of them were traditionally classified as proinflammatory/pronociceptive, such as SP, or CGRP, whereas others alleviate and balance the neurogenic response (e.g. somatostatin or galanin). Besides its profound role in nociceptive transmission, the neurogenic component has been implicated in immune-mediated diseases, such as rheumatoid arthritis (RA)

relatively early (Levine *et al.* 1985). Later it has been proven that this phenomenon significantly contributes to the formation of the inflammatory microenvironment by eliciting vasodilation, vascular permeability increase, mast cell degranulation and leukocyte egress, collectively termed neurogenic inflammation (Keeble *et al.* 2004). This has been suggested as a pivotal factor in autoimmune inflammatory conditions (Stangenberg *et al.* 2014).

We have previously observed, that selective desensitization of peptidergic sensory nerves by RTX leads to diminished pain perception, and surprisingly increased inflammation severity in experimental arthritis, asserting a protective role to the TRPV1-expressing sensory terminals (Helyes *et al.* 2004). Thus, our aim was to further characterize, and preferentially attribute these effects to specific mediators released by peptidergic sensory afferents, using translational models of peripheral neuropathy and inflammatory conditions.

## **PACAP - implications in pain and inflammation**

PACAP is a prominent member of the VIP/secretin/glucagon peptide family expressed in a 27 and 38 aminoacid-containing isoforms (PACAP-27 and -38 respectively). PACAP-38 is the predominant form in mammals. It is expressed ubiquitously in the nervous system and various non-neural tissues (blood vessels, immune cells). It is anti-hyperalgesic on the periphery, while pronociceptive in the CNS. Therefore, PACAP has been suggested to play a crucial role in central sensitization and the induction of chronic pain (Vaudry *et al.* 2009). The role of PACAP in inflammation and immunoregulation has been investigated to a lesser extent, however it was suggested to be an important endogenous immunomodulator. Traditionally three G-Protein-Coupled Receptors (GPCR) were considered to be the targets of PACAP. On one of these (PAC<sub>1</sub>) PACAP is the sole endogenous agonist, whereas its potency on the VPAC<sub>1</sub> and VPAC<sub>2</sub> receptors is similar to that of VIP (Laburthe *et al.* 2007). PACAP-27 has been proved to be able to also activate the Formyl Peptide Receptor-Like 1 (FPRL1) as well (Kim *et al.* 2006). The PAC<sub>1</sub> receptor is expressed mainly on neural and smooth muscle cells, whereas the VPAC<sub>1</sub>/VPAC<sub>2</sub> receptors are localized primarily on the DRG, sensory nerve terminals, and inflammatory cells (Vaudry *et al.* 2009). PACAP receptors are also widely distributed in the immune system: PAC<sub>1</sub> receptor is expressed on macrophages and monocytes. VPAC<sub>1</sub> was found on lymphocytes, macrophages, and monocytes, whereas the VPAC<sub>2</sub> receptor is only expressed on stimulated lymphocytes and macrophages (Delgado *et al.* 2003). The FPRL1 receptor is expressed on leukocytes and lymphocytes (Kim *et al.* 2006).

## **The functional importance of tachykinins**

Three tachykinin encoding genes have been cloned up to now (Tac1, Tac3, and Tac4). However, due to post-translational modifications the diversity of the peptides is larger. The first identified Tac1 gene encodes primarily SP and NKA, the Tac3 gene encodes NKB, whereas the Tac4 gene produces hemokinin, the most recently discovered members of the tachykinin family (Page 2005). SP and NKA are expressed in both neural, vascular and immune cells. They elicit diverse effects, such as neurogenic vasodilation and plasma protein extravasation, visceral smooth muscle contraction (Keeble *et al.* 2004), stimulation of lymphocyte proliferation, cytokine production, T cell chemotaxis and neutrophil accumulation. They facilitate the release of histamine and serotonin through mast cell activation, which consequently increases the neuropeptide-release from the sensory nerves through positive feedback (Szallasi *et al.* 1999). Three G-protein coupled tachykinin receptors have been identified: Neurokinin 1, 2, and 3 (NK1; NK2; NK3, respectively; Maggi 1995). Although all tachykinins activate all receptors, SP is considered to be the main endogenous agonist on the NK1, NKA on the NK2, and NKB on the NK3 receptor. However hemokinin is also a potent agonist on the NK1 receptor. The NK1 receptor demonstrates ubiquitous expression, however, the highest expression levels were reported in the CNS (Pinto *et al.* 2004).

## **Galanin Receptor 3 – an emerging target in neurogenic inflammation**

Galanin is a sensory neuropeptide that is expressed ubiquitously in the nervous system. Later studies revealed the existence of other closely related peptide mediators such as Galanin-Like Peptide (GALP), and its splice variant alarin, which altogether form the galanin peptide family (Lang *et al.* 2015). The role of galanin has been described in a wide range of physiologic processes, such as nociception, inflammation. Galanin, GALP, and alarin mediate their effects through three different GPCRs (termed GalR1-3). Galanin was found to be a potent agonist on GalR1 and GalR2 but not on GalR3, while GALP has high affinity only towards GalR3 and GalR2 (Webling *et al.* 2012). Both GalR1 and GalR2 are present in abundance throughout the CNS whereas GalR3 expression in the brain is limited. Thus, it was hypothesised that these two receptors mediate galaninergic effects in nociceptive transmission. In non-neural tissues mainly GalR2 and GalR3 are expressed. Due to its limited expression in the CNS, GalR3 received less attention than the other receptors. However, since it is the predominant galaninergic receptor on the periphery the interest for this receptor is growing, especially as recent findings also indicate the presence of other endogenous GalR3 agonists surpassing the potency of galanin (Kim *et al.* 2014).

# EXPERIMENTAL MODELS AND METHODS

## Animals

The experiments were done on 10-14 week-old male PACAP, Tac1, Tacr1 and GalR3 gene-deficient mice and their respective wildtype counterparts. For the increasing temperature hot-plate test female mice were also used. PACAP<sup>-/-</sup> mice were generated on the outbred CD1 background (*Osaka University, Japan*). SP and NKA deficient (Tac1<sup>-/-</sup>) (*University of Liverpool, UK*) and NK1 receptor gene-deleted (Tacr1<sup>-/-</sup>) (*University of Bonn, Germany*) mice were generated on the inbred C57Bl/6 background (Helyes *et al.* 2010). GalR3<sup>-/-</sup> (LEXKO-230) mice were obtained from the European Mouse Mutant Archive.

## Partial nerve ligation model of traumatic mononeuropathy

Animals were anesthetized and one-third of the the right common sciatic nerve was unilaterally tightly ligated using an atraumatic suture. (Seltzer *et al.* 1990). Based on our earlier results, this model is both reliable and highly reproducible.

## K/BxN serum-transfer model of autoimmune arthritis

The genetically engineered K/BxN mouse strain displays spontaneous polyarthritis characterized by the production of autoantibodies and other inflammatory mediators. Transfer of serum from the K/BxN mice elicits a robust, albeit transient polyarthritis (dominated by neutrophils and macrophages) (Korganow *et al.* 1999). The arthritis was induced by i.p. injection of the arthritogenic (K/BxN) or control (BxN) serum.

## The oxazolone-induced model of atopic contact dermatitis

Repeated cutaneous challenge with the allergenic hapten oxazolone induces an atopic contact dermatitis (ACD)-like delayed type hypersensitivity reaction in mice. This is a primarily Th1 lymphocyte-mediated inflammation with a consequent activation of mast cells and recruitment of neutrophils and mononuclear cells (Petersen *et al.* 2006). Mice were sensitized on two consecutive days by oxazolone smearing on the abdominal skin, and elicitation was performed 6 days later on the ear (Bánvölgyi *et al.* 2005).

## Evaluation of mechano- and thermonociception

The mechanonociceptive threshold was measured on the plantar surface of the hindlimb with a dynamic plantar esthesiometer. Thermonociceptive threshold was also determined on the hindlimb using an increasing temperature hot plate.

## **Assessing motor coordination and grasping ability**

Motor functions were studied using an accelerating Rota-Rod device. Arthritic joint dysfunction was also evaluated by the horizontal wire mesh grid test.

## **Imaging the cutaneous blood flow (laser Doppler scanning)**

Microcirculation in the plantar skin of the hindpaw was measured by laser Doppler imaging. Mice were anesthetized, their body temperature was maintained with a controlled heating pad. First, control images of the plantar surfaces of both the operated and the intact hindpaws were taken to establish a solid baseline blood flow. Then freshly prepared AITC (mustard oil) was smeared on the hindlimbs in order to elicit a TRPA1-driven vasodilatory response. The plantar microcirculation was measured for ~60 minutes after AITC application.

## **Evaluation of arthritis severity and hindpaw edema**

The severity of the arthritis including the hyperemia and paw edema were determined daily by the means of semiquantitative clinical scoring of both hindlimbs between 0 and 10. The hindpaw volume increase was evaluated by plethysmometry.

## ***In vivo* fluorescence imaging of vascular leakage**

We dissolved the fluorescent marker indocyanine-green (ICG) using the non-ionic surfactant Kolliphor HS 15 into a micellar solution (Kirchherr *et al.* 2009), which limits the blood clearance of the dye to sites affected by increased vascular permeability. This formula was injected i.v. to anesthetized mice which were thereafter imaged with an IVIS Lumina II optical imager. During some later studies we employed IR-676 instead of ICG, a more suitable fluorophore enabling lower dosage and more sensitive detection. Standardized regions of interests (ROIs) were drawn around the ankle joints, and the fluorescence intensity was quantified within these regions.

## **Investigation of free radical production *in vivo***

Luminol is a chemiluminescent compound, which can be utilised to detect the activity of the myeloperoxidase (MPO) enzyme *in vivo*. The reaction occurs mainly in the presence of H<sub>2</sub>O<sub>2</sub>, which is primarily produced by the phagosomal MPO of activated neutrophils. Thus, it is an indirect, but highly selective tool to investigate MPO-activity in a noninvasive manner (Gross *et al.* 2009). Mice received luminol i.p. and were imaged 10 min later with the IVIS

Lumina II. ROIs of identical size were applied around the joints, and luminescence was quantified.

Lucigenin is also a chemiluminescent compound that reacts with the extracellular superoxide produced primarily by the NADPH-oxidase enzyme of active macrophages in inflammation (Tseng *et al.* 2012). Lucigenin solution was injected i.p., and bioluminescence imaging was performed as described earlier and was also evaluated in a similar manner.

### ***In vivo* micro-computed tomography (micro-CT) analysis**

Micro-CT imaging was performed using the same mice at every time-point to minimize inter-individual differences. The ankles were repeatedly scanned by a SkyScan 1176 micro-CT. After the reconstruction, the bone structure was analyzed. ROIs were drawn around the periarticular region of the tibia and fibula, as well as the tibiotarsal and tarsometatarsal joints based on anatomical landmarks. In the ROIs bone volume and bone surface were calculated and expressed as % of the standardized total volume of the ROI.

### **Evaluation of ear edema**

Ear thickness was measured with a microcaliper on the pinna of the ear. Measurements were taken from the same relative position before and after oxazolone-treatment.

### **Histology**

PACAP<sup>+/+</sup> and PACAP<sup>-/-</sup> mice were sacrificed on day 4 and 28 GalR3<sup>+/+</sup> and GalR3<sup>-/-</sup> mice on the 14<sup>th</sup> day under deep anesthesia. The ankle joints were fixed in paraformaldehyde, decalcified, dehydrated and embedded in paraffin. Sections were made and stained with safranin O and semiquantitatively evaluated by a pathologist. Synovial cell proliferation and mononuclear cell infiltration were scored (0-normal state, 3-maximal severity). The ears of GalR3<sup>+/+</sup> and GalR3<sup>-/-</sup> mice were taken upon completion of the *in vivo* experimental readouts 48 hours post oxazolone-challenge and stained with hematoxylin-eosin (HE).

### **Statistical analysis**

Statistical evaluation was performed by the GraphPad Prism<sup>®</sup> software package. All data were expressed as means±SEM. The majority of the functional results was evaluated by repeated measures or two-way ANOVA. Simple comparisons were made using unpaired t-test. The Kaplan-Meier curves were analyzed by logrank test. P<0.05 was considered significant.

# AIMS

In the present work we examined the pathophysiological relevance of three distinct peptide mediator groups. Our aims were the following:

1. **To investigate the role of PACAP and Tac1-gene derived tachykinins, particularly SP and the NK1 receptor in a mouse model of traumatic neuropathy.** Both PACAP and SP/NKA are prominent representatives of sensory neuropeptides, and have been implicated in both peripheral and central pain conditions. PACAP has been shown to play a role in pain, while tachykinins, but most importantly the NK1 receptor were until recently also considered to be a promising target for analgesic drug candidates. Here we aimed to evaluate their effect on mechanical hyperalgesia, motor coordination, and peripheral vasoregulation under normal and neuropathic conditions.
2. **To analyze the effect of PACAP, Tac1-gene derived tachykinins, and the NK1 receptor in a murine rheumatoid arthritis model.** Since PACAP is not only a nerve-driven mediator, but it is also expressed by numerous non-neural cells, we employed a broad range of readouts to address its function in nociception, inflammation, and neurovascular interactions. The fact that this peptide has a distinct specific receptor (PAC<sub>1</sub>) renders it particularly important in context of potential drug developmental perspectives. Tachykinins, but particularly SP were among the earliest neuropeptide candidates implicated in RA, however later results proved to be contradictory, some results supporting, while others opposing their role in nerve-driven inflammation.
3. **To examine the role of the galanin receptor 3 in the pathophysiology of inflammation.** Galanin is widely acclaimed due to its anti-inflammatory and analgesic properties. However, little is known about its downstream signaling and targets on a receptorial level. Due to its low expression in neural tissues GalR3 received particularly little attention until recently. Its profound presence in the periphery, especially around blood vessels indirectly suggested, it might be among the receptors responsible for the manifold anti-inflammatory effects of galanin-family peptides. Here we examined the role of GalR3 in inflammatory disease models for the first time, using translational murine models of RA and atopic contact dermatitis.

# RESULTS AND DISCUSSION

## ***1. The role of PACAP, Tac1 gene-derived tachykinins, and NK1 receptor in a traumatic mononeuropathy mouse model***

Since PACAP and tachykinins are colocalized in peptidergic sensory nerve terminals, our main goal was to investigate their roles using the Seltzer-model (unilateral partial sciatic nerve ligation) of traumatic mononeuropathy and global PACAP, SP/NKA, and NK1 receptor knockout mouse strains. Additionally, the potential involvement of the NK1 receptor, the main target of SP, was also addressed. This was because results obtained using solely Tac1 gene-deficient animals leave completely unexplained whether the possible differences in the parameters investigated are due to the lack of SP or NKA.

### **Mechanical hyperalgesia**

Tight ligation of one-third of the sciatic nerve induced a significant decrease of the threshold of the affected hindpaw in wildtype animals. In comparison, neuropathic mechanical hyperalgesia was negligible in the PACAP<sup>-/-</sup> group. SP/NKA or NK1 receptor deficiency did not influence the mechanonociceptive threshold during the whole study.

### **Motor coordination and performance**

The basal motor performance on the accelerating Rota-Rod was significantly worse in both the PACAP<sup>-/-</sup> and Tac1<sup>-/-</sup> groups compared to respective wildtypes. In contrast, deletion of the NK1 receptor did not influence motor coordination. The partial sciatic nerve ligation did not affect performance in any of the groups.

### **Cutaneous blood flow of the hindpaw and neurogenic vasodilation**

After AITC-challenge a significantly lower perfusion was detected in the PACAP<sup>-/-</sup> group from the 30<sup>th</sup> minute onwards. In the Tac1<sup>-/-</sup> and Tac1<sup>-/-</sup> groups the basal cutaneous microcirculation was significantly lower on both limbs compared to C57Bl/6 wildtypes but the response elicited by AITC was similar in knockouts

Our results provide evidence that: 1) PACAP is a crucial mediator of neuropathic hyperalgesia. 2) Under normal conditions both PACAP and Tac1 gene-derived tachykinins play an important role in motor coordination. 3) Tachykinins regulate the basal cutaneous microcirculation via NK1 receptor activation, whereas PACAP is involved in neurogenic vasodilation. 4) Partial ligation of the sciatic nerve, which is a widely used traumatic mononeuropathy model, induces purely sensory neuropathy (mechanical hyperalgesia) without affecting the motor and vascular functions. Although the sciatic nerve contains sensory, motor and autonomic fibers, partial ligation is affecting exclusively the sensory functions.

## ***2. The role of PACAP, Tac1 gene-derived tachykinins, and NK1 receptor in a murine model of autoimmune arthritis***

Based on the prior results, we decided to investigate the role of PACAP, Tac1-gene derived tachykinins, and the NK1 receptor using global gene-deficient mice in the K/BxN serum-transfer model of autoimmune arthritis, which relies at least partially on neurogenic mediators and a functioning peripheral innervation (Stangenberg *et al.* 2014). Thus, it provides a state-of-the-art workhorse model for studying the effect of neuro-immune and neuro-vascular interactions in a complex, disease-mimicking experimental setup. First we aimed to establish the overall effect of these peptidergic mediators using functional readouts. Promising candidates would be then further interrogated using more elaborate methods, placing special emphasis on the vascular phase, as this is the most important parameter influenced by neurogenic messengers.

### **Arthritic mechanical and thermal hyperalgesia**

A significant mechanical hyperalgesia developed after arthritis induction in wildtypes, which was absent in the arthritic PACAP gene-deficient mice. Thermal hyperalgesia was found to be absent in this model of autoimmune arthritis. In the experiments involving Tac1 and Tacr1 gene-deficient mice, the arthritic mechanical hyperalgesia developed similarly to their wildtype controls, with no observable differences in the early or late phase of the disease.

## **Hindlimb edema and disease severity**

The hindpaw volume was markedly reduced in PACAP<sup>-/-</sup> mice. The edema was not only significantly smaller, but the kinetics was also slower. Semiquantitative clinical scoring of edema and hyperemia yielded a comparable outcome, PACAP<sup>-/-</sup> mice had overall significantly lower arthritis severity scores. In contrast, neither the Tac1, nor the Tacr1 gene-deficient mice displayed any difference regarding disease severity, or hindlimb edema compared to the C57Bl/6 wildtype mice.

## **Microvascular plasma leakage in the inflamed hindlimbs**

Two days after the induction of arthritis the accumulation of ICG increased remarkably in the ankle joints of wildtypes both immediately after injection and 1 hour later, indicating hyperemia and plasma leakage. In contrast, in PACAP-deficient animals, the rise was significantly less pronounced.

## **Alteration of grasping ability and motor coordination**

The horizontal wire grid grip-test revealed an abrupt decrease of grasping ability in wildtypes, but not in PACAP<sup>-/-</sup> animals. Motor performance on the Rota-Rod gradually improved in all groups during the experiment demonstrating learning. Therefore it was concluded that the Rota-Rod test is inadequate to measure functional incapacitance in this model. The performance of Tac1 and Tacr1 gene-deficient mice proved to be indifferent from their wildtype controls.

## **Neutrophil-derived MPO-activity**

Bioluminescence imaging showed that MPO-activity in the inflamed ankle joints peaked in the hyperacute phase of the disease, reaching its maximum on day 1 and gradually decreasing thereafter. In PACAP<sup>-/-</sup> mice early MPO-activity was significantly smaller, but by day 4 it became significantly greater.

## **Macrophage-derived superoxide production**

In PACAP<sup>+/+</sup> mice extracellular superoxide production increased steadily upon arthritis induction. Superoxide generation in PACAP<sup>-/-</sup> mice remained significantly lower than in wildtypes.

## **Micro-CT imaging of bone structural changes**

The control micro-CT-scans of intact mice revealed that PACAP<sup>-/-</sup> animals have different bone architecture even under normal condition. Their Bone Volume/Total Volume (BV/TV) ratio was consistently, although not significantly higher. Arthritis did not remarkably alter the bone structure in neither PACAP<sup>+/+</sup> nor PACAP<sup>-/-</sup> mice in the region of the ankle joint. In contrast, in PACAP<sup>-/-</sup> mice it induced extensive, progressive osteophyte formation in the periarticular region of the tibia and fibula. These bone spurs turned into compact, dense bone leading to a prominent, significant increase of bone mass.

## **Histopathologic alterations in the ankle joints**

Four days after arthritis induction there were prominent changes in the wildtype group: 1) Irregular cartilage-bone border, 2) Enlarged synovium infiltrated with inflammatory cells 3) Massive infiltration of the periarticular connective tissue by immune cells and formation of mononuclear cell aggregates. Synovial hyperplasia, but not cellular infiltration was greater in PACAP<sup>-/-</sup> mice. By day 28 these acute inflammatory signs decreased, but the cartilage-bone border became more irregular and the cartilage width remarkably decreased in both groups.

The primary outcome of our study is that we provided the first evidence for a surprisingly pleiotropic effect of PACAP on various characteristics of a RA disease model. According to our results PACAP increases vasodilation, plasma leakage, inflammatory cell accumulation, hyperalgesia, functional loss and ROS generation, while abrogating late phase inflammatory cell activity, synovial proliferation and pathological bone formation. Contrarily, our results about the role of SP/NKA and the NK1 receptor do not support their involvement in this model of autoimmune arthritis, This is in good agreement with our earlier negative results discussed extensively in the previous chapter. Secondly, this model proved to be appropriate to investigate several early and late phase characteristics of RA using *in vivo* non-invasive imaging modalities. We adopted and modified structural and optical imaging techniques, as

well as self-controlled experimental paradigm that help to identify key pathophysiological mechanisms in inflammatory and degenerative joint diseases.

### **3. The role of Galanin receptor 3 in a mouse model of autoimmune arthritis and atopic contact dermatitis**

It was previously demonstrated that galanin has anti-inflammatory, and primarily antiedema effects in rodent inflammation models (Lang *et al.* 2011). As the main galaninergic receptor on the periphery GalR3 was found to be a promising candidate among the presumed mediators of this antiedema effect on a receptorial level (Schmidhuber *et al.* 2009). On the basis of these prior results we aimed to investigate the potential involvement of GalR3 activation in mouse models of immune-mediated inflammatory diseases, placing special emphasis on the edema formation and inflammatory cell activity. We have selected the K/BxN serum transfer model of RA, and the oxazolone-model of ACD for this purpose.

#### **Arthritis severity mechanical hyperalgesia and change of joint function**

Clinical severity scoring and plethysmometry both indicated an accelerated disease induction in GalR3<sup>-/-</sup> mice until the 6<sup>th</sup> day following arthritis induction. However wildtype mice reached only slightly lower peak values. A considerable and similar mechanonociceptive threshold drop was observed in both groups with no observable differences between wildtypes and knockouts. Joint function of the mice decreased steadily without any differences between groups.

#### **Plasma leakage and MPO-activity in the arthritic hindlimbs**

The plasma leakage measured by ICG was found to be greater in the paws of GalR3<sup>-/-</sup> mice on day 1 than in arthritic wildtypes, however this significant difference vanished by day 5. The MPO-activity of activated neutrophils peaked in both groups during the hyperacute phase of the disease, with no significant difference between the study groups.

## **Histology of arthritic ankle joints**

Structural interrogation of joint samples taken for histology 14 days after K/BxN serum-challenge revealed mainly alterations characteristic of chronic arthritis. The synovial lining was thickened, and the adipocyte-rich connective tissue was replaced with a dense fibroblastic scar tissue, with a limited presence of inflammatory cells. No difference was observed in these respects between the study group, in agreement with the absent functional difference at this stage of the disease.

## **Ear edema, MPO-activity, plasma extravasation, and histology**

A considerable and similar ear thickness increase could be observed following oxazolone-challenge in both groups, which peaked at 24 h. MPO activity and microvessel permeability also increased dramatically after 24 hours, however no difference could be observed between the wildtypes and knockouts with any of the readouts employed. The histology of the ear lobes by HE staining confirmed the considerable thickening of the connective tissues, inflammatory cell infiltration, the dilation of the ear microvasculature, and the presence of a considerable amount of exsudate in both groups between the ear cartilage and the subcutis.

Our results suggest that GalR3 is a mediator of endogenous protective mechanisms in inflammatory arthritis initiated by neurogenic vascular responses. However taking into consideration the most recent forthcoming, the observed effect in our model is not necessarily galanin-mediated (Kim *et al.* 2014). The absent difference in the neutrophil-derived MPO-activity highlights that the heightened inflammatory reaction in knockouts is caused entirely by the increased vascular leakiness, and not by GalR3-mediated effects on the polymorphonuclear cells. The absence of difference in the ACD model may suggest that the GalR3-mediated antiedema effect is only encountered if the disease model in question is triggered by neurogenic vasodilation in the early phase. In our point of view the way of the formation of the inflammatory microenvironment is a key difference between these two models, in the K/BxN serum-transfer model there is a very early neurogenic permeability increase of the microvessels around the joints (Stangenberg *et al.* 2014), which enables inflammatory cell recruitment. In contrast in the cell-mediated oxazolone-model is initiated by the locally present dendritic and T cells, with consequent permeability increase and leukocyte influx (Petersen *et al.* 2006). Thus the absence of the antiedema effect of galanin through GalR3 will presumably not have a noticeable impact on the disease course.

## SUMMARY AND MAIN CONCLUSIONS

In the present study we have provided a comprehensive picture on the effects of several peptidergic mediators in pain and inflammation, where the main emphasis was placed on the disease development *in vivo*.

1. PACAP is pronociceptive in not only peripheral traumatic neuropathy but also in autoimmune arthritis.
2. PACAP and SP/NKA are both involved in motor coordination.
3. PACAP is a key mediator of neurogenic vasodilation, while SP/NKA and the NK1 receptor have a crucial role in the maintenance of normal vascular tone.
4. PACAP affects arthritis development in a complex manner. It increases hyperemia, plasma leakage and edema.
5. PACAP increases early neutrophil-accumulation by facilitating their extravasation from the vessels, but it diminishes their function in the later phase. In contrast, it promotes macrophage-activity and ROS production, but limits inflammation-induced pathological bone neoformation and synovial degeneration.
6. Mice deficient in SP/NKA or the NK1 receptor develop the same degree of arthritis undisturbedly, suggesting that the pathways represented by these mediators can be either bypassed, or that they do not constitute a pivotal mechanism in the development of the serum transfer arthritis.
7. GalR3 mediates important antiedema functions in during nerve-driven inflammation but it is not involved in arthritic pain signaling and does not directly affect inflammatory cell functions. Thus, endogenous agonists of GalR3 might be considered as protective or regulatory factors which balance and limit the extent of the vascular phase of neurogenic inflammation.

## ACKNOWLEDGEMENTS

I would like to thank my supervisor, Prof. Zsuzsanna Helyes for tutoring me through all these years, and for introducing me as a student research fellow into the world of biomedical research. I am most grateful to Prof. Erika Pintér, the of the Neuropharmacology doctoral program and head of the institute for giving me the opportunity to work and study in her school. I would like to express my gratitude to Prof. János Szolcsányi, the founder of this research group and to Prof. Loránd Barthó, the former head of the institute.

I would like to also thank the members of the research group for constantly advising and helping me through all these years regarding both the theoretical and technical parts of the research and for sharing their expertise with me, especially Kata Bölcskei, Ágnes Kemény, Éva Borbély, Valéria Tékus, Zsófia Hajna.

I wish to express my sincere thanks to Anikó Perkecz, Dóra Ömböli, Nikolett Szentes, and Tamás Kiss for their valuable technical assistance in our experiments.

Many thanks go to our collaborators, Prof. Dóra Reglődi, Prof. Attila Mócsai, Prof. Barbara Kofler, and Prof. László Kollár for their important contributions, and for providing us with valuable research materials and critical insights.

I wish to thank all members of the institute for their varying but indispensable help.

I am also grateful to my former colleagues and other student research fellows (Krisztián Elekes, András Imreh) for their unceasing encouragement during those early years.

Finally, I would like to thank my parents, family, and friends for supporting and encouraging me through all these years, and my fiancée for her loving care.

## REFERENCES

- Bánvölgyi Á**, et al. Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. *J Neuroimmunol.* 2005;169:86-96.
- Bölcskei K**, et al. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. *Pain.* 2005 Oct;117:368-76.
- Brain SD.** Sensory neuropeptides: their role in inflammation and wound healing. *Immunopharmacology.* 1997;37:133-52.
- Caceres AI**, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. *Proc Natl Acad Sci U S A.* 2009;106:9099-104.
- Caterina MJ**, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 1997;389:816-824.
- Delgado M**, et al. PACAP in immunity and inflammation *Ann N Y Acad Sci.* 2003;992:141-57.
- Gross S**, et al. Bioluminescence imaging of myeloperoxidase activity in vivo. *Nat Med.* 2009;15:455-61.
- Helyes Z**, et al. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. *Arthritis Rheum.* 2004;50:1677-85.
- Helyes Z**, et al. Involvement of preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-induced murine airway inflammation. *Neuropeptides* 2010;44:399-406.
- Jancsó M.** Role of nerve terminals in the mechanism of inflammatory reactions. *Bull. Millard Fillmore Hosp. Buffalo N.Y.* 1960. 7:53-77
- Jancsó M**, et al. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. *Br J Pharmacol Chemother* 1967;31:138-151.
- Keeble JE**, et al. A role for substance P in arthritis? *Neurosci Lett.* 2004;361:176-9.
- Kim DK**, et al. Coevolution of the spexin/galanin/kisspeptin family: Spexin activates galanin receptor type II and III. *Endocrinology.* 2014. 155: 1864-1873.
- Kim Y**, et al. Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1. *J Immunol.* 2006;176:2969-75.
- Kirchherr AK**, et al. Stabilization of indocyanine green by encapsulation within micellar systems. *Mol Pharm.* 2009;6:480-91.
- Korganow AS**, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. *Immunity.* 1999;10:451-61.
- Laburthe M**, et al. Class II G-protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. *Peptides* 2007;28:1631-9.
- Lang R**, et al. The galanin peptide family in inflammation. *Neuropeptides.* 2011. 45: 1-8.
- Lang R**, et al. Physiology, Signaling, and Pharmacology of Galanin Peptides and Receptors: Three Decades of Emerging Diversity. *Pharmacol Rev.* 2015;67:118-175.
- Levine JD**, et al. The contribution of neurogenic inflammation in experimental arthritis. *J Immunol.* 1985;135:843-847.
- Maggi CA**, et al. The sensory-efferent function of capsaicin-sensitive sensory neurons. *Gen. Pharmacol.* 1988;19:1-43.
- Maggi CA.** The mammalian tachykinin receptors. *Gen Pharmacol* 1995;26:911-44.
- Nilius B**, et al. The transient receptor potential family of ion channels. *Genome Biol.* 2011;12:218.
- Page NM.** New challenges in the study of the mammalian tachykinins. *Peptides* 2005;26:1356-68.
- Petersen TK.** In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. *Basic Clin Pharmacol Toxicol.* 2006. 99 :104-15.
- Pinto FM**, et al. mRNA expression of tachykinins and tachykinin receptors in different human tissues. *Eur J Pharmacol* 2004;494:233-9.
- Pozsgai G**, et al. Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. *Cardiovasc Res.* 2010;87:760-8.
- Schmidhuber SM**, et al. Evidence that the modulatory effect of galanin on inflammatory edema formation is mediated by the galanin receptor 3 in the murine microvasculature. *J Mol Neurosci.* 2009. 37: 177-181.
- Seltzer Z**, et al. A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. *Pain* 1990;43:205-18.
- Stangenberg L**, et al. Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature. *Proc Natl Acad Sci U S A.* 2014;111:11419-24.
- Szallasi A**, et al. Vanilloid (capsaicin) receptors and mechanisms. *Pharmacol Rev* 1999;51:159-212.
- Szolcsányi J.** Forty years in capsaicin research for sensory pharmacology and physiology. *Neuropeptides* 2004;38:377-384.
- Tominaga M**, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron* 1998;21:531-543.
- Vaudry D**, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. *Pharmacol Rev* 2009;61:283-357.
- Webling KE**, et al. Galanin receptors and ligands. *Front Endocrinol (Lausanne).* 2012;3:146.

# LIST OF PUBLICATIONS

## Articles related to thesis:

*Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions.* **Botz B**, Imreh A, Sándor K, Elekes K, Szolcsányi J, Reglődi D, Quinn JP, Stewart J, Zimmer A, Hashimoto H, Helyes Z. *Peptides*. 2013 13;43:105-112. (IF: 2.614)

*Differential regulatory role of Pituitary Adenylate-Cyclase Activating Polypeptide in the serum-transfer-induced arthritis model.* **Botz B**, Bölcskei K, Kereskai L, Kovács M, Németh T, Szigeti K, Horváth I, Máthé D, Kovács N, Hashimoto H, Reglődi D, Szolcsányi J, Pintér E, Mócsai A, Helyes Z. *Arthritis Rheumatol*. 2014 66;10:2739–2750. (IF: 7.477\*)

*A role for galanin receptor 3 in reducing murine autoimmune arthritis, but not contact dermatitis.* **Botz B**, Kemény Á, Brunner S, Janka C, Mócsai A, Pintér E, McDougall JJ, Kofler B, Helyes Z (manuscript under review)

*Capsaicin-sensitive sensory nerves exert important protective functions in the serum transfer arthritis model of the mouse.* Borbély É, **Botz B**, Bölcskei K, Kenyér T, Kereskai L, Kiss T, Szolcsányi J, Pintér E, Csepregi J, Mócsai A, Helyes Z. (co-first author) *Brain Behav. Immun*. 2014 Dec 15. doi: 10.1016/j.bbi.2014.12.012. [Epub ahead of print] (IF: 5.813\*) (50% of the article)

## Articles not related to the thesis:

*Hydrophobic cyanine dye-doped micelles for optical in vivo imaging of plasma leakage and vascular disruption.* **Botz B**, Bölcskei K, Kemény Á, Sándor Z, Tékus V, Sétáló G Jr, Csepregi J, Mócsai A, Pintér E, Kollár L, Helyes Z. *J Biomed Opt*. 2015;20(1):16022. (IF: 2.945\*)

*Role of Pituitary Adenylate-Cyclase-Activating Polypeptide in nociception and migraine.* Tuka B, Tajti J, **Botz B**, Helyes Z, Vécsei L. *CNS Neurol Disord Drug Targets*. [article in press] (IF: 3.298\*)

*Hemokinin-1 is an important mediator of endotoxin-induced acute airway inflammation in the mouse.* Hajna Z, Borbély É, Kemény Á, **Botz B**, Kereskai L, Szolcsányi J, Pintér E, Paige CJ, Berger A, Helyes Z. *Peptides* 2014 Dec 22 [Epub ahead of print] (IF: 2.552\*)

*Hck, Fgr and Lyn are critical for the generation of the in vivo inflammatory milieu without a direct role in leukocyte recruitment.* Kovács M, Németh T, Jakus Z, Sitaru C, Simon E, Futosi K, **Botz B**, Helyes Z, Lowell CA, Mócsai A. *J Exp Med* 2014 211:1993-2011 (IF: 14.1\*)

*The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin.* Banki E, Hajna Z, Kemény A, **Botz B**, Nagy P, Bölcskei K, Toth G, Reglődi D, Helyes Z. *Neuropharmacology*. 2014 Oct;85:538-47. (IF: 4.386\*)

*Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice.* Sándor K, Kormos V, **Botz B**, Imreh A, Bölcskei K, Gaszner B, Markovics A, Szolcsányi J, Shintani N, Hashimoto H, Baba A, Reglődi D, Helyes Z. *Neuropeptides*. 2010 44:363-71. (IF: 1.917)

*Current approaches in the treatment of neuropathic and phantom limb pain.* Helyes Zs, **Botz B** (e-book-chapter)

(\*5-year impact factor)

Cumulative impact factor (without citable abstracts): 45.102

Citations: 30

Independent citations: 13

## Presentations related to the thesis:

*A galanin 3 receptor szerepének vizsgálata reumatoid artritisz és atópiás kontakt dermatitisz egérmodelljeiben.* **Botz B**, Kemény Á, Csepregi J, Mócsai A, Locker F, Brunner S, Kofler B, Pintér E, Helyes Z A Magyar

Kísérletes és Klinikai Farmakológiai Társaság Experimentális Farmakológiai szekciójának IX. szimpóziuma (March 26-28, 2015, Velence)

*A kapszaicin-érzékeny érző idegvégződések komplex szabályozó szerepe rheumatoid arthritis egérmodelljében* **Botz B**, Borbély É, Kenyér T, Bölcskei K, Csepregi J, Mócsai A, Kereskai L, Z Helyes. (III. Pécs-Oklahoma Symposium (POS) December 18, 2014, Pécs)

*Peptidergic sensory nerves exert important regulatory role in experimental immune arthritis.* **Botz B**, Borbély É, Kenyér T, Bölcskei K, Csepregi J, Mócsai A, Kereskai L, Z Helyes. (The 11th International Medical Postgraduate Conference November 27–28, Hradec Králové, Czech Republic)

*Peptidergic sensory nerves are important regulators in experimental immune arthritis* **Botz B**, Borbély É, Kenyér T, Bölcskei K, Kiss T, Németh T, Kovács M, Mócsai A, Szolcsányi J, Pintér E, Helyes Z. (8th International Symposium on Cell/Tissue Injury and Cytoprotection/Organoprotection, September 24-26, 2014, Budapest)

*The immunoregulatory role of galanin receptor 3 in experimental arthritis* **Botz B**, Kovács M, Németh T, Mócsai A, Brunner S, Kofler B, Pintér E, Helyes Z (20th international Symposium on Regulatory Peptides (REGPEP 2014), September 7-10, 2014, Kyoto, Japan)

*Peptidergic sensory nerves play an important regulatory role in murine immune arthritis* **Botz B**, Borbély E, Kenyér T, Bölcskei K, Kiss T, Németh T, Kovács M, Mócsai A, Kereskai L, Szolcsányi J, Pintér E, Helyes Z (20th international Symposium on Regulatory Peptides (REGPEP 2014), September 7-10, 2014, Kyoto, Japan)

*Evidence for the involvement of galanin receptor 3 in an inflammatory arthritis model of the mouse* **Botz B**, Kovács M, Németh T, Mócsai A, Brunner S, Kofler B, Pintér E, Helyes Z. (Joint meeting of FEPS and the Hungarian Physiological Society, Budapest, Hungary, August 27-30, 2014.)

*Neuro-immun interakciók szerepének vizsgálata reumatoid arthritis mechanizmus-modelljében* **Botz B** (Nemzeti Kiválóság Program a Pécsi Tudományegyetemen, March 20., 2014, Pécs)

*Divergent roles of PACAP in nociception and inflammation in the serum transfer arthritis model of the mouse* **Botz B**, Kovács M, Horváth I, Szigeti K, Máthé D, Hashimoto H, Reglődi D, Németh T, Mócsai A, Helyes Z (Semmelweis Symposium 2013, November 7-9. 2013, Budapest)

*Role of capsaicin-sensitive peptidergic sensory nerves in collagen antibody-induced arthritis* **Botz B**, Borbély É, Szabadfi K, Kiss T, Szolcsányi J, Helyes Z (Neuroinflammation Satellite Symposium of the FENS meeting Prague, Czech Republic, September 8-11., 2013)

*Roles of Pituitary Adenylate-Cyclase Activating Polypeptide (PACAP) in nociception and inflammation in an immune mediated arthritis model* **Botz B**, Horvath I, Szigeti K, Veres D, Mathe D, Hashimoto H, Reglodi D, Nemeth T, Kovacs M, Mocsai A, Helyes Zs (The 11th International Symposium on VIP, PACAP and Related Peptides, August 27-31. 2013, Pécs)

*The role of PACAP and Tac1 gene derived tachykinins in a mouse model of traumatic mononeuropathy* **Botz B**, Imreh A, Sandor K, Elekes K, Reglodi D, Quinn JP, Stewart J, Zimmer A, Hashimoto H, Szolcsanyi J, Helyes Zs (The 11th International Symposium on VIP, PACAP and Related Peptides, August 27-31. 2013, Pécs)

*Investigation of the role of capsaicin-sensitive sensory nerves in a mouse polyarthritis model using in vivo imaging techniques* **Botz B**, Borbély É, Bölcskei K, Nagy P, Németh T, Kovács M, Mócsai A, Szolcsányi J, Helyes Z (From Medicine to Bionics – 1st International PhD. conference, June 13-15. 2013, Budapest)

*A hipofízis adenilát-cikláz aktiváló polipeptid (PACAP) gyulladá- és fájdalomkeltő szerepe K/BxN szérum-transzfer arthritis egérmodellben* **Botz B**, Horváth I, Szigeti K, Veres D, Máthé D, Hitoshi H, Reglődi D, Németh T, Mócsai A, Helyes Z (A Magyar Élettani, Farmakológiai, és Mikrocirkulációs Társaságok 2013. évi közös kongresszusa, June 05-08. 2013, Budapest)

*Pro-inflammatory and pro-nociceptive roles of Pituitary Adenylate-Cyclase Activating Polypeptide (PACAP) in a serum transfer arthritis mouse model* **Botz B**, Horváth I, Szigeti K, Veres D, Máthé D, Hashimoto H, Reglődi D, Németh T, Kovács M, Mócsai A, Helyes Z (Neuropeptides 2013 conference May 29.- June 01. 2013, Gdynia, Poland)

*Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1 gene derived tachykinins in sensory, motoric and vascular functions under normal and neuropathic conditions.* **Botz B**, Imreh A, Sándor K, Elekes K, Szolcsányi J, Reglődi D, Quinn JP, Stewart J, Zimmer A, Helyes Z. (XIVth Conference of the Hungarian Neuroscience Society January 17-19. 2013, Budapest, Hungary)

*Investigating the role of Pituitary adenylate-cyclase activating polypeptide in a mouse model of traumatic mononeuropathy* **Botz B**, Imreh A, Helyes Z (8th international Biomedical Croatian Student Summit, May 28-31. 2012, Zagreb, Croatia)

*Investigating the role of Pituitary adenylate-cyclase activating polypeptide in a mouse model of traumatic mononeuropathy – possible new therapeutic perspectives.* **Botz B**, Imreh A, Elekes K, Szőke É, Sándor K, Reglődi D, Pintér E, Szolcsányi J, Hashimoto H, Helyes Z (Amerikai Magyar Orvosszövetség (HMAA Hungary Chapter) Balatonfüredi éves konferenciája August 19-20. 2011, Balatonfüred.)

*Investigating the role of tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions.* **Botz B**, Imreh A, Elekes K, Quinn JP, Szolcsányi J, Helyes Z (A Farmakológus, Anatómus, Mikrocirkulációs, Élettani társaságok 2011. évi közös tudományos konferenciája, June 8-11. 2011, Pécs)

*Hipofízis adenilát-cikláz aktiváló polipeptid (PACAP) génhiányos egerek szenzoros és motoros funkcióinak vizsgálata normál és neuropátiás körülmények között.* **Botz B**, Imreh A (A Magyar Élettani Társaság (MÉT) LXXIV. Vándorgyűlése és a Magyar Kísérletes és Klinikai Farmakológiai Társaság (MFT) II. közös tudományos konferenciája, June 16-18. 2010, Szeged)

*A kapszaicin-érzékeny érzőideg-végződéses komplex szabályozó szerepe szérum-transzfer arthritis egérmodelljében* Helyes Z, Borbély É, **Botz B**, Mócsai A, Németh T, Kovács M, Kereskai L, Bölcseki K, Pintér E, Kenyér T, Szolcsányi J (Erdélyi Múzeum-Egyesület, Orvos- és Gyógyszerésztudományi Szakosztály, XXIV. Tudományos Ülésszak, Marosvásárhely, April 24-26. 2014, Marosvásárhely)

*Complex regulatory role of capsaicin-sensitive peptidergic nerves in the serum-transfer arthritis model* Helyes Z, Borbély É, **Botz B**, Kenyér T, Kiss T, Németh T, Mócsai A, Pintér E, Szolcsányi J (11th World Congress on Inflammation, September 21-25. 2013, Natal, Brazil)

*Role of the capsaicin-sensitive sensory nerves in autoantibody-induced arthritis of the mouse* Borbély É, **Botz B**, Kenyér T, Kiss T, Pintér E, Szolcsányi J, Kovács M, Németh T, Mócsai A, Helyes Z (Neuropeptides 2013 conference May 29.- June 01.2013 Gdynia, Poland)

*A kapszaicin-érzékeny érzőideg-végződéses szerepének vizsgálata immunarthritis egérmodelljében* Borbély É, **Botz B**, Kiss T, Pintér E, Szolcsányi J, Németh T, Mócsai A, Helyes Z (A Magyar Élettani, Farmakológiai, és Mikrocirkulációs Társaságok 2013. évi közös kongresszusa, June 05-08. 2013, Budapest)

### **Other presentations:**

*Development and characterization of a novel murine passive-transfer-trauma model for Complex Regional Pain Syndrome (CRPS).* Tékus V, **Botz B**, Szentés N, Hajna Z, Borbély É, Scheich B, Szőke É, Thompson V, Goebel A, Helyes Z (15th Biannual Conference of the Hungarian Neuroscience Society, January 22-23, 2015, Budapest, Hungary)

*Fájdalomcsillapító és gyulladáscsökkentő gyógyszerek hatásának állatkísérletes vizsgálata* **Botz B** (Agykutatás hete programsorozat, March 12. 2013, Pécs)

*Role of the Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel in the acute and chronic inflammatory pain models using gene-deficient mice* Tékus V, Horváth Á, **Botz B**, Szolcsányi J, Pintér E, Helyes Z (Joint meeting of FEPS and the Hungarian Physiological Society, Budapest, Hungary, August 27-30., 2014.)

*The influence of the neuropeptide galanin on the immune system* Kofler B, Brunner S, Locker F, Koller A, Bianchini R, Lang A, Wiesmayr S, McDougall J, **Botz B**, Szitter I, Helyes Z (The 2nd International meeting on Nerve-driven immunity, Neurotransmitters and Neuropeptides In The Immune System and In Neuroimmune Dialogues, August 20-21., 2014. Nobel Forum, Karolinska Institute, Stockholm, Sweden)

*Src-family kinases in neutrophils are required for creating an inflammatory environment in autoimmune arthritis* Kovács M, Simon E, Németh T, Jakus Z, **Botz B**, Zs. Helyes, Lowell CA., Mócsai A (Simmelweis Symposium 2013, November 7-9. 2013, Budapest)

*Investigation of the role of capsaicin-sensitive sensory nerves in murine autoantibody-induced arthritis* Borbély É, **Botz B**, Kenyér T, Kiss T, Pintér E, Szolcsányi J, Kovács M, Németh T, Mócsai A, Helyes Z (Simmelweis Symposium 2013, November 7-9. 2013, Budapest)

*Capsaicin-sensitive sensory nerves play an important role in murine autoantibody-induced arthritis* Borbély É, **Botz B**, Kenyér T, Kiss T, Pintér E, Szolcsányi J, Németh T, Mócsai A, Helyes Z (Neuroinflammation satellite symposium of the FENS meeting September 8-11., 2013, Prague, Czech Republic)

*Role of capsaicin-sensitive afferents and sensory-immune interactions in arthritis* Helyes Z, Borbély É, **Botz B**, Tékus V, Hajna Z, Sándor K, Markovics A, Pintér E, Szolcsányi J, Quinn JP, Berger A, McDougall JJ (Neuroinflammation satellite symposium of the FENS meeting September 8-11., 2013, Prague, Czech Republic)

*A hipofízis adenilát-cikláz aktiváló polipeptid szerepének vizsgálata egér fájdalom-modellekben.* Helyes Z, Markovics A, Sándor K, Kormos V, Gaszner B, Szőke É, **Botz B**, Imreh A, Pintér E, Szolcsányi J, Hashimoto H, Reglődi D (A Farmakológus, Anatómus, Mikrocirkulációs, Élettani társaságok 2011. évi közös tudományos konferenciája, Pécs June 08-11. 2011, Pécs)

*Role of pituitary adenylate cyclase activating polypeptide in the nitroglycerin-induced migraine model of the mouse.* Markovics A, Sandor K, Szoke E, Kormos V, **Botz B**, Imreh A, Gaszner B, Reglodi D, Baba A, Tajti J, Szolcsanyi J, Helyes Z (16th World Congress on Basic and Clinical Pharmacology July 17-23. 2010, Copenhagen, Denmark)

*Role of pituitary adenylate cyclase activating polypeptide in nocifensive behaviours, inflammatory and neuropathic hyperalgesia.* Sandor K, Kormos V, **Botz B**, Imreh A, Bölcskei K, Gaszner B, Reglodi D, Szolcsanyi J, Shintani N, Hashimoto H, Baba A, Helyes Z (16th World Congress on Basic and Clinical Pharmacology July 17-23. 2010, Copenhagen, Denmark)

*Role of Pituitary Adenylate Cyclase- Activating Polypeptide in nociceptive processes: behavioural and immunohistochemical studies.* Sándor K, Kormos V, Imreh A, **Botz B**, Bölcskei K, Gaszner B, Reglődi D, Szolcsányi J, Shintani N, Hashimoto H, Baba A, Helyes Z: (IBRO International Workshop January 21-23. 2010, Pécs, Hungary)

*Role of pituitary adenylate-cyclase activating polypeptide in mouse models of nocifensive behaviours and hyperalgesia.* Helyes Z, Sándor K, Kormos V, **Botz B**, Imreh A, Bölcskei K, Szolcsányi J, Norihito S, Hashimoto H, Baba A, Reglődi D (Poster presentation at the 12th Meeting of the Hungarian Neuroscience Society (HNS) January 22-24., 2009 - Budapest)

*Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal hyperalgesia in pituitary adenylate-cyclase activating polypeptide deficient mice* Sándor K, Kormos V, **Botz B**, Imreh A, Bölcskei K, Reglődi D, Szolcsányi J, Hashimoto H, Baba A, Helyes Z (Winter Neuropeptide Conference 2009, January 31. – February 3. 2009 Breckenridge, Colorado, USA)